Unasnemab

Unasnemab (MT-3921) is a humanised IgG1 monoclonal antibody that binds to repulsive guidance molecule A (RGMa) . Unasnemab improves locomotor function and promotes neuroregeneration. Unasnemab exerts ameliorative effects on hippocampal neurogenesis impairment and cognitive decline in db/db mice, Streptozotocin (STZ) (HY-13753) -induced type 1 diabetic and bilateral common carotid artery stenosis (BCAS) -induced mice. Unasnemab can be used for the research of spinal cord injury, diabetes-induced neurological impairments[1][2][3].

Product Specifications

CAS Number

[2379805-59-9]

Product Name Alternative

MT-3921; rH116A3

UNSPSC

12352203

Target

TGF-β Receptor

Type

Inhibitory Antibodies

Related Pathways

TGF-beta/Smad

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/unasnemab.html

Purity

99.00

Solubility

H2O

Smiles

[Unasnemab]

Molecular Weight

(144.88 kDa)

References & Citations

[1]Araya N, et al. Virus-induced RGMa expression drives neurodegeneration in HTLV-1-associated myelopathy. JCI Insight. 2025 Apr 24;10 (11) :e184530. |[2]Uno H, et al. Inhibition of repulsive guidance molecule A ameliorates diabetes-induced cognitive decline and hippocampal neurogenesis impairment in mice. Commun Biol. 2025 Feb 19;8 (1) :263. |[3]Yamamoto M, et al. Anti-RGMa neutralizing antibody ameliorates vascular cognitive impairment in mice. Neurotherapeutics. 2025 Mar;22 (2) :e00500.